Duration of GLP-1 Receptor Agonist Therapy and Nephrolithiasis Risk in Type 2 Diabetes: A Multicenter Retrospective Cohort Study
- Design
- Retrospective cohort
- Drugs
- Class unspecified
- Assessment
- Not yet reviewed by a person · added Oct 18, 2026
This study was added automatically and has not been reviewed. Until it is, the collection publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved. This item has not been peer reviewed.
01Source
The source, as retrieved
Abstract
<title>Abstract</title> <p>Purpose Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic control and metabolic health, but their association with nephrolithiasis remains poorly defined. We evaluated the relationship between GLP-1 RA exposure duration and incident nephrolithiasis among adults with type 2 diabetes mellitus (T2DM). Methods Using the TriNetX Research Network, adults with T2DM were stratified according to GLP-1 RA exposure as no exposure, < 1 year, 1–3 years, or 3–5 years. Patients with chronic kidney disease, prior nephrolithiasis, bariatric surgery, or prior sodium-glucose cotransporter-2 inhibitor exposure were excluded. Pairwise propensity score matching and time-to-event analyses were performed. Two complementary analyses were conducted: a broader T2DM cohort evaluating nephrolithiasis risk across GLP-1 RA exposure durations and a secondary cohort restricted to patients with at least 5 years of established T2DM. Results In the broader T2DM cohort, shorter GLP-1 RA exposure was associated with higher nephrolithiasis risk. No exposure was associated with greater risk than < 1 year of exposure (HR 1.037, 95% CI 1.010–1.065; p = 0.006), < 1 year was associated with greater risk than 1–3 years (HR 1.071, 95% CI 1.008–1.138; p = 0.028), and 1–3 years was associated with greater risk than 3–5 years (HR 1.189, 95% CI 1.075–1.315; p = 0.001). In the cohort restricted to patients with at least 5 years of T2DM, no significant differences were observed among the longer GLP-1 RA exposure-duration comparisons, indicating the absence of a progressive duration-response relationship in patients with established diabetes. Conclusion Longer GLP-1 RA exposure was associated with lower nephrolithiasis risk in the broader T2DM population. However, this duration-response relationship was not observed among patients with at least 5 years of established T2DM. These findings suggest that the association between GLP-1 RA exposure duration and nephrolithiasis may differ according to diabetes chronicity and warrant prospective investigation.</p>
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| europepmc | Sep 27, 2026 | PPR:PPR1323050 first ingestion |
| europepmc | Oct 4, 2026 | PPR:PPR1323050 duplicate matched on doi |